A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
Tanya Simuni,Lana M Chahine,Kathleen Poston,Michael Brumm,Teresa Buracchio,Michelle Campbell,Sohini Chowdhury,Christopher Coffey,Luis Concha-Marambio,Tien Dam,Peter DiBiaso,Tatiana Foroud,Mark Frasier,Caroline Gochanour,Danna Jennings,Karl Kieburtz,Catherine M Kopil,Kalpana Merchant,Brit Mollenhauer,Thomas Montine,Kelly Nudelman,Gennaro Pagano,John Seibyl,Todd Sherer,Andrew Singleton,Diane Stephenson,Matthew Stern,Claudio Soto,Caroline M Tanner,Eduardo Tolosa,Daniel Weintraub,Yuge Xiao,Andrew Siderowf,Billy Dunn,Kenneth Marek
DOI: https://doi.org/10.1016/s1474-4422(23)00405-2
IF: 59.935
2024-01-24
The Lancet Neurology
Abstract:Summary Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical features, with α-synuclein pathology as the gold standard to establish the definitive diagnosis. We propose that, given biomarker advances enabling accurate detection of pathological α-synuclein (ie, misfolded and aggregated) in CSF using the seed amplification assay, it is time to redefine Parkinson's disease and dementia with Lewy bodies as neuronal α-synuclein disease rather than as clinical syndromes. This major shift from a clinical to a biological definition of Parkinson's disease and dementia with Lewy bodies takes advantage of the availability of tools to assess the gold standard for diagnosis of neuronal α-synuclein (n-αsyn) in human beings during life. Neuronal α-synuclein disease is defined by the presence of pathological n-αsyn species detected in vivo (S; the first biological anchor) regardless of the presence of any specific clinical syndrome. On the basis of this definition, we propose that individuals with pathological n-αsyn aggregates are at risk for dopaminergic neuronal dysfunction (D; the second biological anchor). Our biological definition establishes a staging system, the neuronal α-synuclein disease integrated staging system (NSD-ISS), rooted in the biological anchors (S and D) and the degree of functional impairment caused by clinical signs or symptoms. Stages 0–1 occur without signs or symptoms and are defined by the presence of pathogenic variants in the SNCA gene (stage 0), S alone (stage 1A), or S and D (stage 1B). The presence of clinical manifestations marks the transition to stage 2 and beyond. Stage 2 is characterised by subtle signs or symptoms but without functional impairment. Stages 2B–6 require both S and D and stage-specific increases in functional impairment. A biological definition of neuronal α-synuclein disease and an NSD-ISS research framework are essential to enable interventional trials at early disease stages. The NSD-ISS will evolve to include the incorporation of data-driven definitions of stage-specific functional anchors and additional biomarkers as they emerge and are validated. Presently, the NSD-ISS is intended for research use only; its application in the clinical setting is premature and inappropriate.
clinical neurology